Submitted by Merck KGaA, Darmstadt, Germany
For these reasons, Merck is supporting and implementing the Joint Position of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). Merck's initiative affects all trials ongoing as of July 1, 2005, and subsequent trials and is formalized under Merck's Global Policy on Clinical Trials Registration and Results Disclosure.
"Merck is committed to providing information and transparency about the clinical trials it conducts," said Thomas Lander, Executive Vice President Global Clinical R&D. "It is our goal to build mutual trust among all participants in the healthcare enterprise: physicians, patients, healthcare providers, clinical trial investigators, government agencies and pharmaceutical manufacturers".
Clinical Trial Registration
First, Merck will register key protocol information for all of its confirmatory trials at their initiation in the publicly accessible, free clinical trial registry ClinicalTrials.gov.
Clinical Trial Results Disclosure
Second, Merck will provide a brief summary of the results of trials in the publicly accessible, free clinical results database ClinicalStudyResults.org. The results will be provided only for confirmatory trials of marketed products completed after January 2005 and be available within one year of product launch or subsequent trial completion.
Merck will also endeavor to publish results of all clinical trials in medical literature and will continue to do so as stated in our Publication Policy. Posting of summary results in ClinicalStudyResults.org will follow publication in these cases.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.subscribe.merck.de to register online, change your selection or discontinue this service.
Merck is a global pharmaceutical and chemical company with sales of EUR 5.9 billion in 2004, a history that began in 1668, and a future shaped by 28,600 employees in 54 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 73% interest and free shareholders own the remaining 27%. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917.
Copyright Business Wire 2005
More from Merck KGaA, Darmstadt, Germany